Numerex Corp. (NASDAQ:NMRX) shares moved up 3.04% in last trading session and ended the day at $8.80. NMRX Gross Margin is 44.90% and its has a return on assets of 0.50%. Numerex Corp. (NASDAQ:NMRX) quarterly performance is 3.53%.
On 22 September, Numerex Corp. (NASDAQ:NMRX) said that, its new managed service from Numerex, is built on Numerex’s cloud-based nxFAST software application, used for locating and tracking valuable assets outfitted with Numerex sensors. This service includes all provisioning and subscription services that a customer needs to quickly launch the iManage platform.
EP Energy Corporation (NYSE:EPE) ended the last trading day at $6.44. Company weekly volatility is calculated as 8.78% and price to cash ratio as 55.25. EP Energy Corporation (NYSE:EPE) showed a weekly performance of 32.78%.
Equities research analysts at Citigroup Inc. cut their price objective on shares of EP Energy Corporation (NYSE:EPE) from $9.50 to $5.00 in a research note issued to investors on Monday, Market Beat.com reports. The firm currently has a “sell” rating on the stock. Citigroup Inc.’s target price would indicate a potential downside of 4.03% from the company’s previous close.
On 05 October, Comcast Corporation (NASDAQ:CMCSA) shares moved up 1.53% and was closed at $59.62. CMCSA EPS growth in last 5 year was 20.50%. Comcast Corporation (NASDAQ:CMCSA) year to date (YTD) performance is 4.07%.
Comcast Corporation (NASDAQ:CMCSA) said that, it will host a conference call with the financial community to discuss financial results for the third quarter on Tuesday, October 27, 2015 at 8:30 a.m. Eastern Time (ET). Comcast will issue a press release reporting its results earlier that morning.
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) shares moved down -0.67% in last trading session and ended the day at $1.98. PIRS has a return on assets of -133.80%. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) quarterly performance is -25.41%.
On 30 September, Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) announced that Professor Gary Anderson, PhD, FThorSoc, FERS, and Director of the Lung Health Research Centre at the University of Melbourne, presented preclinical data on PRS-060, the Company’s inhaled IL4Ra antagonist, at a podium presentation during the 2015 annual meeting for the European Respiratory Society (ERS) in Amsterdam, The Netherlands.
Medgenics, Inc. (NYSEMKT:MDGN) caters to the Healthcare space. Its weekly performance is -11.90%. On the last day of trading company shares ended up at $6.96. Medgenics, Inc. (NYSEMKT:MDGN) distance from 50-day simple moving average (SMA50) is -13.20%.
On 1 October, Medgenics, Inc. (NYSEMKT:MDGN) announced the pricing of 6,155,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $6.50 per share. In connection with the offering, Medgenics has also granted the underwriters a 30-day option to purchase up to an additional 923,250 shares of its common stock. Gross proceeds to Medgenics from the sale of shares are expected to be approximately $40 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock.
Leave a Reply